Bienvenue sur le forum !
Si vous souhaitez rejoindre la communauté, cliquez sur l'un de ces boutons !
>> Forum privé (partage d'analyses)
Catégories
- 1.2K Toutes les catégories
- 3 Autres classes d'actifs
- 4 Podcast
- 15 Débuter en Bourse
- 6 Club partage d'analyses
- 19 Portefeuilles
- 31 Medici
- 39 Finances personnelles
- 394 Discussion sur un titre
- 16 Livres
- 469 La Bourse en général
- 42 Fiscalité
- 59 L'économie en général
- 34 Pas de rapport avec la Bourse
- 60 Rencontre 5 à 7
- 21 Humour
- 49 Forum
Biosyent (rx-v)
Connectez-vous ou Inscrivez-vous pour commenter.
Réponses
Je crois qu'il va falloir attendre l'année 2018 pour collecter ces revenus prometteurs.
http://www.insidetoronto.com/community-story/7093071-donors-help-bring-cysview-technology-to-humber-river-hospital-s-urology-department/
Très bons résultats ce matin.
http://www.biosyent.com/q4-16/#.WMkvWE0zXug
J'ai l'impression que Cysview a faite une grosse part de croissance dans ce trimestre. Si oui je ne suis pas prêt à dire que ce trimestre devient une référence de base.
Mais on voit que lorsque Cysview et les 2produits cardiaques à venir procureront des revenus récurrents, les bpa vont exploser.
sales of its other pharmaceutical products in 2016, including FeraMax® Powder and RepaGyn®
,
for which the domestic sales volumes (units) grew by 27% and 65%, respectively, over 2015 sales
volumes.
The Company’s Hospital Business achieved significant growth in percentage terms in 2016 over
2015 with the successful re-launch of Aguettant System® Atropine Sulphate PFS during the year.
Sales volumes of Cathejell®
Jelly 2% (units) also served as a significant growth driver, with sales
volumes increasing by 17% in 2016 over 2015 sales volumes. Newly launched products,
Cysview® and Aguettant System® PFS Phenylephrine Hydrochloride, also contributed to the
growth of the Hospital Business in 2016. Sales of both of these products occurred late in the
year.
The Canadian launch of Cysview® has been met with enthusiasm from the Canadian urological
community, with an endorsement from leading members of the Canadian Urological Association
(CUA) for the use of Cysview®
in non-muscle invasive bladder cancer. The 2016 sales of
Cysview®
fell short of management’s expectations; however, progress has been made with key
opinion leaders in the urological community and key decision-makers in hospitals in gaining
recognition of Cysview® as an emerging standard of treatment for non-muscle invasive bladder
cancer.
Cysview®, which was launched in November 2015, is experiencing a longer than anticipated
selling cycle with urology centres across Canada due to the need to synchronize the capital
spending budget of hospitals for the purchase of new blue-light cystoscopy-enabled urology
equipment with the selling activities of the manufacturer of this blue-light enabled equipment. In
order to facilitate the budgetary discussions with hospitals and agencies, the Company has
invested in a health economic study to demonstrate the cost effectiveness of adopting Cysview®
for the detection and treatment of non-muscle invasive bladder cancer. This together with the
strong clinical experience at the key opinion leader level with Cysview® as well as the
endorsement of the use of Cysview® by Canadian key opinion leaders lets management believe
that the foundation for future sales has been set. Therefore, the Company was encouraged by a
significant order of Cysview® from a Canadian hospital in the fourth quarter of 2016.
The Company has now recorded sales to a total of five countries outside Canada, including
orders shipped to two new countries in 2016. On a quarter-over-quarter basis, Q4
international FeraMAX® sales of $496,617 were 202% higher compared to Q4 2015 sales of
$164,490.
Management’s Discussion and Analysis
As at March 14, 2017
18
Although sales of FeraMAX® to international customers have now been recorded in eight
consecutive quarters, international sales are typically high in terms of size and dollar value, but
low in terms of frequency. As such, there is significant variability in the level of international sales
from one quarter to the next and one period to the next. The Company continued to see growth
in international sales of its FeraMAX® products during 2016, with sales of $1,549,538 increasing
by 36% over 2015 sales of $1,142,035. This growth is despite the fact that additional production
and logistical complexities in the international pharmaceutical business resulted in a delay in
shipping a large, single international customer order received in 2016. Management previously
anticipated that the order would be shipped in the fourth quarter of 2016, as indicated in its MD&A
for the three and nine months ended September 30, 2016; however, shipment did not occur until
Q1 2017.
https://link.springer.com/content/pdf/10.1007/s00345-017-2077-6.pdf
its financial results for the three and six months ended June 30, 2017. Key highlights include:
Record second quarter (Q2) 2017 Net Revenues of $5,636,405 increased by 29% versus Q2 2016
First half (H1) 2017 Net Revenues of $9,457,667 increased by 16% versus H1 2016
Q2 2017 Pharmaceutical Net Revenues of $5,075,518 increased by 27% versus Q2 2016 with Canadian
Pharmaceutical Net Revenues of $4,335,998 increasing by 16% versus Q2 2016 and International Pharmaceutical
Net Revenues of $739,520 increasing by 188% versus Q2 2016
H1 2017 Pharmaceutical Net Revenues of $8,728,352 increased by 16% versus H1 2016 with Canadian
Pharmaceutical Net Revenues of $7,690,695 increasing by 9% versus H1 2016 and International Pharmaceutical
Net Revenues of $1,037,657 increasing by 103% versus H1 2016
Q2 2017 EBITDA1 of $2,023,234 increased by 45% versus Q2 2016
H1 2017 EBITDA1 of $3,214,558 increased by 21% versus H1 2016
Q2 2017 Net Income After Tax (NIAT) of $1,552,918 increased by 53% versus Q2 2016
H1 2017 NIAT of $2,454,474 increased by 25% versus H1 2016
Q2 2017 NIAT percentage to Net Revenues of 28% compares to 23% in Q2 2016
H1 2017 NIAT percentage to Net Revenues of 26% compares to 24% in H1 2016
Q2 2017 Fully Diluted EPS of $0.11 was 57% higher than Q2 2016 Fully Diluted EPS of $0.07
H1 2017 Fully Diluted EPS of $0.17 was 21% higher than H1 2016 Fully Diluted EPS of $0.14
Trailing Twelve Months Fully Diluted EPS of $0.33 for the twelve months ended June 30, 2017 was 22% higher as
compared to $0.27 for the twelve months ended June 30, 2016
As at June 30, 2017, the Company had cash, cash equivalents, and short term investments totalling $14,702,627
as compared to $13,739,286 as at December 31, 2016 – a 7% increase
At June 30, 2017, the Company remained free of debt and had available total credit facilities of $2,559,000
including an unutilized revolving demand credit facility of $1,500,000
Total Shareholders’ Equity increased by 16% from $16,726,716 at December 31, 2016 to $19,359,333 at June 30,
2017
Trailing Twelve Months Return on Equity for the twelve months ended June 30, 2017 was 33%
“Q2 2017 was a record quarter for BioSyent, bolstered by our established brands and by continued growth in our
international markets” commented René Goehrum, President and CEO of BioSyent. “We are pleased to have
delivered a 28% net margin along with strong sales growth in the second quarter. While we continue to invest in
growing our launch brands, our overall H1 2017 sales growth of 16% is in line with our expectations and the solid net
margin of 26% for H1 2017 is in line with our strategy of delivering profitable growth.”
Je n'ai par contre pas aimé le prêt de 391$K à des "senior management" pour l'achat d'actions. J'espère le voir réduire ou disparaître au prochain trimestre.
On dirait bien que l'investissement dans l'organisation a porté fruit ce trimestre. Le coût des opérations en % est de beaucoup inférieur à la croissance des ventes.
Le prix de l'action est toujours bien évalué.
http://www.biosyent.com/rx/corporate_management/#.Wa31DcjyjIU
http://www.biosyent.com/q3-17/q3-17_pr.pdf
In 2014, 8,000 Canadians were diagnosed with bladder cancer – that year there were 2,200 deaths from bladder cancer. The current treatment is inadequate and costly, says Barkin, adding that “early diagnosis of NMIBC is essential to minimizing the risk of recurrence or progression to muscle invasive disease.”
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve
months ended December 31, 2017. Key highlights include:
International Pharmaceutical Net Revenues of $868,917 increased by 75% versus Q4 2016
International Pharmaceutical Net Revenues of $2,476,902 increased by 60% versus FY 2016
$19,338,435 as compared to $13,739,286 as at December 31, 2016 – a 41% increase
December 31, 2017